<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Arch Pharm Pract</journal-id>
      <journal-id journal-id-type="publisher-id">archivepp.com</journal-id>
      <journal-id journal-id-type="publisher-id">Arch Pharm Pract</journal-id>
      <journal-title-group>
        <journal-title>Archives of Pharmacy Practice</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2320-5210</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">archivepp.com-1286</article-id>
      <article-id pub-id-type="doi">10.51847/OfbpAj2FTy</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Treating AI-Generated Medication Plans as Reversible and Auditable Clinical Objects</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>Al-Hinai</surname>
                <given-names>Saif</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Al-Balushi</surname>
                <given-names>Amal</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Al-Maskari</surname>
                <given-names>Mohammed</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Al-Mahruqi</surname>
                <given-names>Sultan</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of Reversible AI Medication Plans, College of Pharmacy, Sultan Qaboos University, Muscat, Oman.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Auditable Clinical AI Objects, College of Pharmacy, University of Nizwa, Nizwa, Oman.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Medication Plan Governance, College of Pharmacy, Dhofar University, Salalah, Oman.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                              E-mail: <email xlink:href="saif.alhinai@squ.edu.om">saif.alhinai@squ.edu.om</email>
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>30</day>
        <month>06</month>
        <year>2026</year>
      </pub-date>
      <volume>17</volume>
      <issue>2</issue>
      <fpage>75</fpage>
      <lpage>83</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Archives of Pharmacy Practice
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Artificial intelligence can generate medication plans that appear clinically coherent while remaining difficult to inspect, update, attribute, or reconstruct. When such plans persist only as prose, their assumptions, supporting evidence, model provenance, professional review, and subsequent modifications may become disconnected from the decisions they influence. This article proposes that an AI-generated medication plan should be represented as a reversible and auditable clinical-information object rather than treated as ephemeral text or an automatically executable medication order. The proposed Auditable Medication-Plan Object Model combines persistent identity, patient- and time-specific context, structured medication actions, rationale, evidence dependencies, uncertainty, model provenance, professional authorization, immutable versions, governance states, and append-only audit events. Material modification creates a successor version without erasing its predecessor. Reversal is separated into informational withdrawal or rollback and, where medication-related action has already occurred, clinical corrective or compensating action. Approval is represented as a version-specific professional decision rather than evidence of correctness or safety. Evaluation should test identity integrity, lineage completeness, state-transition validity, evidence traceability, recoverability, role comprehension, workflow burden, equity implications, and the separation of technical restoration from clinical recovery. The model is an original conceptual synthesis intended to organize future specification, human-factors assessment, workflow simulation, and prospective evaluation. It does not establish clinical effectiveness, medication-safety improvement, regulatory acceptability, legal sufficiency, universal applicability, or deployment readiness.</p>
      </abstract>
      <kwd-group>
                <kwd>Digital pharmacy</kwd>
                <kwd>Artificial intelligence</kwd>
                <kwd>Pharmacy practice</kwd>
                <kwd>Medication safety</kwd>
                <kwd>Human–AI collaboration</kwd>
                <kwd>Clinical decision support</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>